Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 2/2019

RESULTS OF ALENDRONATE TREATMENT IN PATIENTS DIAGNOSED WITH ASEPTIC OSTEONECROSIS OF THE FEMORAL HEAD

KAMAL CONSTANTIN KAMAL 1#, DRAGOȘ OVIDIU ALEXANDRU 2*, OTILIA CONSTANTINA ROGOVEANU 3, DIANA KAMAL 4#, ALICE SANDRA BUTEICĂ 5#, TUDOR ADRIAN BĂLŞEANU 6, CAMELIA PĂNUȘ 7, DANIELA TEODORA MARIA 8#, MAGDALENA RODICA TRĂISTARU 3

1.Family Medicine Department, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania
2 .Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania
3 .Physical and Rehabilitation Medicine Department, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania
4 .Physical and Rehabilitation Medicine Department, Medical Clinic Elga, University of Medicine and Pharmacy of Craiova, 2 Mihai Eminescu Str., 200131, Craiova, Romania
5 .Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania
6 .Department of Physiology, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania
7 .Department of Diabetes, Nutrition and Metabolic Disease, Emergency Clinical County Hospital of Craiova, University of Medicine and Pharmacy of Craiova, 1Tabaci St., 200642, Craiova, Romania
8 .Nephrology Department, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania

Download Full Article PDF

Aseptic osteonecrosis of the femoral head is a disabling condition with plurifactorial aetiology, which affects especially young adults. The purpose of the study was to show that alendronate therapy is useful to these patients. We included 34 patients aged 23 to 62 years old, diagnosed in the evolutionary stages II and III, which were divided into two groups. Patients in the first group received treatment with alendronate-70 mg per week plus 5600 IU cholecalciferol for 2 years and conservative treatment. Group II was not treated with alendronate but only conservatively treated. Patients were evaluated from a clinical, imagistic and functional standpoint. In the final evaluation, the imaging aspects improved in patients in the first group. The dual-energy x-ray absorptiometry (DXA) T score, the visual analogue scale (VAS) and the Harris Hip test statistically increased significantly in patients in the first group.